

February 9, 2009



Oculus Innovative Sciences Announces Fiscal Third Quarter Financial Results and Corporate Update Release and Conference Call

PETALUMA, Calif.--(BUSINESS WIRE)-- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn^(R) Technology platform, today announced that the financial results for its fiscal third quarter ended December 31, 2008, will be released after the U.S. market closes on February 12, 2009. The earnings release will be followed by a conference call at 1:30 p.m. PT (4:30 p.m. ET) on February 12, 2009, to discuss fiscal third quarter results and provide a corporate update to the investment community.

Individuals interested in participating in the conference call may do so by dialing (877) 604-9667 for domestic callers or (719) 325-4899 for international callers. Those interested in listening to the conference call live via the Internet may do so at <http://ir.oculusis.com/events.cfm>. Please log on approximately 30 minutes prior to the presentation in order to register and download the appropriate software.

A telephone replay will be available for 48 hours following the conclusion of the call by dialing (888) 203-1112 for domestic callers, or (719) 457-0820 for international callers, and entering reservation code 3403136. A webcast replay will be available on the site at <http://ir.oculusis.com/events.cfm> for one year following the call.

About Oculus

Oculus Innovative Sciences develops, manufactures and markets a family of products based upon the Microcyn^(R) Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform features a biocompatible, shelf-stable solution containing active oxychlorine compounds that is currently commercialized in the United States, Europe, India, China and Mexico for the treatment of infected wounds. The solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. The company's headquarters are in Petaluma, California, with operations in Europe and Latin America. More information can be found at www.oculusis.com.

Source: Oculus Innovative Sciences, Inc.